Novavax Receives the Tech Council of Maryland's Chairman's Award
May 12 2016 - 8:30AM
GAITHERSBURG, Md., May 12, 2016
(GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage
vaccine company focused on the discovery, development and
commercialization of recombinant nanoparticle vaccines and
adjuvants, today announced it received the Tech Council of
Maryland's (TCM) Chairman's Award. The award was announced at the
TCM Industry Award Celebration on May 11, 2016.
The Chairman's Award is presented
to a member company or individual that best exemplifies excellence
in Maryland's technology or life science industry. The Award
recognizes a company that is a pillar in the community, not only
through market success or job creation, but by consistently giving
back, getting involved and advancing the climate for
innovation.
"Novavax is the embodiment of what
we look for when selecting an honoree for the Chairman's award. The
company has built a successful business, employing 450 people in
Maryland who are developing vaccines that positively impact global
health, and has played an important role in fostering growth of the
state's life sciences community," said Rene B. LaVigne, TCM
chairman-elect and president and CEO of Iron Bow Technologies. "TCM
appreciates Novavax's significant contributions to the association,
the state's economy and innovations in healthcare."
"I am honored to accept this award
on behalf of the entire Novavax team," said Stanley C. Erck,
President and CEO, Novavax. "The Tech Council of Maryland
facilitates a collaborative community of technology and life
science companies who aim to make an impact in our region and
beyond. We are thrilled that this award recognizes the hard work
and dedication of our more than 450 SuperNovas, our groundbreaking
achievements in developing novel vaccines and our commitment to the
Maryland life science and technology community."
About
Novavax
Novavax, Inc. (Nasdaq:NVAX) is a
clinical-stage vaccine company committed to delivering novel
products to prevent a broad range of infectious diseases. Our
recombinant nanoparticles and Matrix-M(TM) adjuvant technology are
the foundation for groundbreaking innovation that improves global
health through safe and effective vaccines. Additional information
about Novavax is available on the Company's
website, novavax.com.
Contact:
Novavax, Inc.
Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer
Andrea N. Flynn, Ph.D.
Associate Director, Investor Relations
ir@novavax.com
240-268-2000
Russo Partners, LLC
David Schull
Todd Davenport, Ph.D.
david.schull@russopartnersllc.com
todd.davenport@russopartnersllc.com
212-845-4271
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Novavax, Inc. via Globenewswire
HUG#2011869
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Apr 2023 to Apr 2024